Maze Therapeutics (MAZE) Slides On Weak Momentum, Is The Current Valuation About Right?
Maze Therapeutics (MAZE) has drawn investor attention after a weak run for the shares, with the price down 24% over the past month and 12% over the past 3 months.
That short-term weakness sits against a tougher backdrop for Maze Therapeutics, with the year-to-date share price return down 43.37% even though the 1-year total shareholder return is only 1.83% lower. Momentum has clearly faded, and recent moves suggest investors are reassessing both growth potential and clinical or funding risks around the current US$22.52 share price.
Scan beyond Maze Therapeutics and compare its recent pullback with hand-picked biopharma peers by reviewing the 16 high quality undiscovered gems that are still flying under most investors' radar.
Maze Therapeutics now trades at US$22.52 while analyst targets cluster far higher. So where does fair value actually land across that wide range, and what does that spread suggest about the risk investors are pricing in?
Preferred Price-to-Book of 2.8x for Maze Therapeutics: Is it justified?
On simple valuation maths, Maze Therapeutics trades on a P/B of 2.8x, which is far below hand picked peers at 22.7x, even though it sits slightly above the broader US Pharmaceuticals group on 2.4x. At a $22.52 share price and a value score of just 1 out of 6, the market is clearly wrestling with how to price a clinical stage pipeline alongside ongoing losses.
The P/B ratio compares the equity value on the stock market to the accounting book value of net assets, which matters a lot for early stage biopharma where earnings are still negative. For Maze Therapeutics, a 2.8x multiple means investors are willing to pay $2.80 for each $1 of net assets. This reflects expectations around future trial outcomes and eventual commercialisation rather than current profitability.
Against a peer average P/B of 22.7x, Maze Therapeutics trades at a much lower multiple, which strongly suggests investors in this smaller group of comparables are attaching far richer expectations elsewhere. Relative to the wider US Pharmaceuticals industry average of 2.4x, the stock sits on a premium valuation. This points to the market assigning some extra value to the pipeline, even though MAZE is currently unprofitable and reported a net loss of $133.59m on $20.0m of revenue.
Result: Price-to-book of 2.8x (ABOUT RIGHT)
See what the numbers say about this price — find out in our valuation breakdown.
Still, Maze Therapeutics faces clear pressure points, including ongoing losses of $133.59m on $20.0m of revenue and the execution risk around multiple phase II programs.
Find out about the key risks to this Maze Therapeutics narrative.
Next Steps
Mixed feelings about Maze Therapeutics so far. If you want to move from headline moves to your own view, start with the 1 key reward and 4 important warning signs
Looking for more investment ideas beyond Maze Therapeutics?
If Maze Therapeutics has sharpened your thinking on risk and reward, do not stop here. Broaden your watchlist with other ideas that match your style.
- Target resilient balance sheets and steady fundamentals by reviewing the list of solid balance sheet and fundamentals (23 results) to help anchor a more defensive core.
- Hunt for quality at a discount and scan the 33 high quality undervalued stocks to find companies that combine strong business profiles with pricing that still looks reasonable.
- Prioritise sleep-at-night stability and filter for the 30 resilient stocks with low risk scores to help smooth portfolio swings when volatility picks up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com